Acetazolamide in Aneurysmal Subarachnoid Hemorrhage

Phase 2

Completed

Conditions: hemorrhagic stroke
stroke
subarachnoid hemorrhage
10021666
10002363

Registration Number: NL-OMON50004

Lead Sponsor: Radiologie

Brief Summary: Trial ended prematurely

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

>=18 years old
Aneurysm confirmed by the presence of subarachnoid blood by computed tomography (CT) or lumbar puncture and by visualization of the aneurysm on either CT angiography, MR angiography or digital subtraction angiography
Hospital arrival <=120 hours of ictus
Adequate treatment of the aneurysm

Exclusion Criteria

Intensive care (IC) required for >120 hours after ictus (i.e., during inclusion window)
Perimesencephalic bleeding
Traumatic SAH
Severe liver dysfunction or severe renal dysfunction
Allergic reaction for sulfomides
Any contraindication for MR imaging (e.g. metal objects within or around the body)
Pregnancy or women who are breastfeeding
Addison*s disease
Phenytoin use

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Cerebral perfusion (arterial spin labeling (ASL) MRI) on day 7±2 after ictus.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Cerebral perfusion (arterial spin labeling (ASL) MRI) on day 12±2 after ictus.<br /><br>Serious adverse events (SAEs) and serious unexpected serious adverse reactions<br /><br>(SUSARs) until 10 weeks after ictus.<br /><br>The occurrence of DCI. DCI will be defined as either clinical deterioration or<br /><br>cerebral infarction due to delayed cerebral ischemia.</p><br>